Enfusion, Clearwater and Investment Management

Clearwater agrees to buy investment management platform Enfusion for $1.5B
Clearwater Analytics said it has entered into a definitive agreement to acquire investment management platform Enfusion for $1.5 billion.
Clearwater acquires Enfusion in $1.5B financial software deal
Clearwater Analytics Holdings Inc. today announced plans to acquire Enfusion Inc., a fellow provider of financial software, for $1.5 billion in cash and stock.
Clearwater to acquire Enfusion to expand its Investment Management Platform
IBS Intelligence (IBSi) is the world’s only pure-play Financial Technology focused research, advisory, and fintech news analysis firm, with a 30-year track record and clients globally. We take pride in covering 400+ technology vendors globally – the largest by any analyst firm in this space.
Clearwater Analytics Buys Enfusion in $1.5 Bln Deal
Clearwater Analytics struck a deal to buy software company Enfusion in a deal worth $1.5 billion, bolstering its efforts to build a cloud platform for the investment-management industry.
Clearwater Analytics acquires software maker Enfusion for $1.5 billion to drive global expansion
Clearwater Analytics has agreed to acquire rival Enfusion in a $1.5 billion cash-and-stock deal as the financial software maker looks to bolster its international presence and enter the hedge fund industry.
Clearwater Analytics upgraded to Buy at DA Davidson on ‘strategic’ Enfusion deal
DA Davidson upgraded Clearwater Analytics (CWAN) to Buy from Neutral with a price target of $32, down from $35. The company’s proposed merger
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Enfusion, Inc. (ENFN) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between ...
Clearwater Analytics to buy software maker Enfusion for $1.5 billion to drive global expansion
Clearwater Analytics has agreed to acquire Enfusion in a $1.5 billion cash-and-stock deal as the financial software maker ...
Enfusion (NYSE:ENFN) Given “Market Perform” Rating at William Blair
Enfusion (NYSE:ENFN – Get Free Report)‘s stock had its “market perform” rating reaffirmed by equities research analysts at ...
Enfusion, Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / January 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...
Clearwater Analytics to Acquire Enfusion for $1.5 Billion Expanding its Investment Management Platform with Front-to-Back Capabilities
Clearwater Analytics (NYSE: CWAN) ("Clearwater") and Enfusion, Inc. (NYSE: ENFN) ("Enfusion") today announced their entry ...
Business Wire2d
ENFUSION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of En…
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are ...
Enfusion downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Michael Infante downgraded Enfusion (ENFN) to Equal Weight from Overweight with a price target of $11.25, up from $11.
Enfusion downgraded to Hold from Buy at Stifel
Stifel analyst J. Parker Lane downgraded Enfusion (ENFN) to Hold from Buy with a price target of $11.25, down from $13, after the company announced an agreement to be acquired by Clearwater Analytics ...